Isis Pharmaceuticals, Inc. announced that the company expects to significantly improve upon its 2014 financial guidance. The company expects to end 2014 with a pro forma net operating loss in the mid to high teens and more than $725 million in cash. The significantly improved financial performance of the company in 2014 was a result of the successful execution of its business strategy, the maturation of its pipeline and the growing validation of antisense as a viable, efficient and effective drug discovery technology.